An essential role for DNA methyltransferase 3a in melanoma tumorigenesis

Biochemical and Biophysical Research Communications

Volumn 387, Issue 3, 2009, Pages 611-616

  Deng, Tao ^a,e   Kuang, Ying ^b   Wang, Long ^b   Li, Jiang ^b   Wang, Zhugang ^b,d   Fei, Jian ^a,b,c  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^b Shanghai Nan Fang Model Organism Research Center   (China)

^c TONGJI UNIVERSITY   (China)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^e UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

DNA methylation; Dnmt3a; Immune escape; Melanoma; Metastasis; Tumorigenesis

Indexed keywords

CXCL16 CHEMOKINE; CXCL9 CHEMOKINE; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 5; TRANSACTIVATOR PROTEIN;

ANIMAL CELL; ARTICLE; CCNE1 GENE; CELL CYCLE REGULATION; CELL SURVIVAL; CONTROLLED STUDY; CYR61 GENE; DEMETHYLATION; DNA METHYLATION; DNA MICROARRAY; E2F6 GENE; ENZYME MECHANISM; GENE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC TRANSFECTION; GROWTH INHIBITION; IMMUNE RESPONSE; IMMUNOMODULATION; MELANOMA; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; RNA INTERFERENCE; SOCS1 GENE; TGFB1 GENE; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; PROMOTER REGIONS, GENETIC; TUMOR ESCAPE;

EID: 68249112132     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.07.093     Document Type: Article

References (41)

1. Miller A.J., and Mihm Jr. M.C. Melanoma. N. Engl. J. Med. 355 (2006) 51-65
2. Herman J.G., and Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349 (2003) 2042-2054
3. Dahl C., and Guldberg P. The genome and epigenome of malignant melanoma. Apmis 115 (2007) 1161-1176
4. Knudson A.G. Hereditary cancer: two hits revisited. J. Cancer. Res. Clin. Oncol. 122 (1996) 135-140
5. Furuta J., Umebayashi Y., Miyamoto K., Kikuchi K., Otsuka F., Sugimura T., and Ushijima T. Promoter methylation profiling of 30 genes in human malignant melanoma. Cancer Sci. 95 (2004) 962-968
6. Hoon D.S., Spugnardi M., Kuo C., Huang S.K., Morton D.L., and Taback B. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene 23 (2004) 4014-4022
7. Spugnardi M., Tommasi S., Dammann R., Pfeifer G.P., and Hoon D.S. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. Cancer Res. 63 (2003) 1639-1643
8. Kohonen-Corish M.R., Cooper W.A., Saab J., Thompson J.F., Trent R.J., and Millward M.J. Promoter hypermethylation of the O(6)-methylguanine DNA methyltransferase gene and microsatellite instability in metastatic melanoma. J. Invest. Dermatol. 126 (2006) 167-171
9. Worm J., Bartkova J., Kirkin A.F., Straten P., Zeuthen J., Bartek J., and Guldberg P. Aberrant p27Kip1 promoter methylation in malignant melanoma. Oncogene 19 (2000) 5111-5115
10. Gonzalgo M.L., Bender C.M., You E.H., Glendening J.M., Flores J.F., Walker G.J., Hayward N.K., Jones P.A., and Fountain J.W. Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors. Cancer Res. 57 (1997) 5336-5347
11. Mirmohammadsadegh A., Marini A., Nambiar S., Hassan M., Tannapfel A., Ruzicka T., and Hengge U.R. Epigenetic silencing of the PTEN gene in melanoma. Cancer Res. 66 (2006) 6546-6552
12. Lei H., Oh S.P., Okano M., Juttermann R., Goss K.A., Jaenisch R., and Li E. De novo DNA cytosine methyltransferase activities in mouse embryonic stem cells. Development 122 (1996) 3195-3205
13. Li E., Bestor T.H., and Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 69 (1992) 915-926
14. Okano M., Bell D.W., Haber D.A., and Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99 (1999) 247-257
15. Baylin S.B., and Herman J.G. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 16 (2000) 168-174
16. Jones P.A., and Laird P.W. Cancer epigenetics comes of age. Nat. Genet. 21 (1999) 163-167
17. Kanai Y., Ushijima S., Kondo Y., Nakanishi Y., and Hirohashi S. DNA methyltransferase expression and DNA methylation of CPG islands and peri-centromeric satellite regions in human colorectal and stomach cancers. Int. J. Cancer 91 (2001) 205-212
18. Robertson K.D., Uzvolgyi E., Liang G., Talmadge C., Sumegi J., Gonzales F.A., and Jones P.A. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res. 27 (1999) 2291-2298
19. Beaulieu N., Morin S., Chute I.C., Robert M.F., Nguyen H., and MacLeod A.R. An essential role for DNA methyltransferase DNMT3B in cancer cell survival. J. Biol. Chem. 277 (2002) 28176-28181
20. Eads C.A., Nickel A.E., and Laird P.W. Complete genetic suppression of polyp formation and reduction of CpG-island hypermethylation in Apc(Min/+) Dnmt1-hypomorphic Mice. Cancer Res. 62 (2002) 1296-1299
21. Rhee I., Bachman K.E., Park B.H., Jair K.W., Yen R.W., Schuebel K.E., Cui H., Feinberg A.P., Lengauer C., Kinzler K.W., Baylin S.B., and Vogelstein B. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 416 (2002) 552-556
22. Deng T., Kuang Y., Zhang D., Wang L., Sun R., Xu G., Wang Z., and Fei J. Disruption of imprinting and aberrant embryo development in completely inbred embryonic stem cell-derived mice. Dev. Growth Differ. 49 (2007) 603-610
23. Chang C.C., and Ferrone S. Immune selective pressure and HLA class I antigen defects in malignant lesions. Cancer Immunol. Immunother. 56 (2007) 227-236
24. Kim R., Emi M., and Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology 121 (2007) 1-14
25. Marsman M., Jordens I., Griekspoor A., and Neefjes J. Chaperoning antigen presentation by MHC class II molecules and their role in oncogenesis. Adv. Cancer Res. 93 (2005) 129-158
26. Chang C.C., Campoli M., and Ferrone S. Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions. Adv. Cancer Res. 93 (2005) 189-234
27. Campoli M., and Ferrone S. HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene 27 (2008) 5869-5885
28. Reith W., and Mach B. The bare lymphocyte syndrome and the regulation of MHC expression. Annu. Rev. Immunol. 19 (2001) 331-373
29. Wright K.L., and Ting J.P. Epigenetic regulation of MHC-II and CIITA genes. Trends Immunol. 27 (2006) 405-412
30. Raman D., Baugher P.J., Thu Y.M., and Richmond A. Role of chemokines in tumor growth. Cancer Lett. 256 (2007) 137-165
31. Ruffini P.A., Morandi P., Cabioglu N., Altundag K., and Cristofanilli M. Manipulating the chemokine-chemokine receptor network to treat cancer. Cancer 109 (2007) 2392-2404
32. Harlin H., Meng Y., Peterson A.C., Zha Y., Tretiakova M., Slingluff C., McKee M., and Gajewski T.F. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 69 (2009) 3077-3085
33. Hojo S., Koizumi K., Tsuneyama K., Arita Y., Cui Z., Shinohara K., Minami T., Hashimoto I., Nakayama T., Sakurai H., Takano Y., Yoshie O., Tsukada K., and Saiki I. High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer. Cancer Res. 67 (2007) 4725-4731
34. Zhang Y., Wen G., Shao G., Wang C., Lin C., Fang H., Balajee A.S., Bhagat G., Hei T.K., and Zhao Y. TGFBI deficiency predisposes mice to spontaneous tumor development. Cancer Res. 69 (2009) 37-44
35. Sutherland K.D., Lindeman G.J., Choong D.Y., Wittlin S., Brentzell L., Phillips W., Campbell I.G., and Visvader J.E. Differential hypermethylation of SOCS genes in ovarian and breast carcinomas. Oncogene 23 (2004) 7726-7733
36. Rottapel R., Ilangumaran S., Neale C., La Rose J., Ho J.M., Nguyen M.H., Barber D., Dubreuil P., and de Sepulveda P. The tumor suppressor activity of SOCS-1. Oncogene 21 (2002) 4351-4362
37. Cartwright P., Muller H., Wagener C., Holm K., and Helin K. E2F-6: a novel member of the E2F family is an inhibitor of E2F-dependent transcription. Oncogene 17 (1998) 611-623
38. Gaubatz S., Wood J.G., and Livingston D.M. Unusual proliferation arrest and transcriptional control properties of a newly discovered E2F family member, E2F-6. Proc. Natl. Acad. Sci. USA 95 (1998) 9190-9195
39. Ohtsubo M., Theodoras A.M., Schumacher J., Roberts J.M., and Pagano M. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol. Cell. Biol. 15 (1995) 2612-2624
40. Mazumder S., DuPree E.L., and Almasan A. A dual role of cyclin E in cell proliferation and apoptosis may provide a target for cancer therapy. Curr. Cancer Drug Targets 4 (2004) 65-75
41. Babic A.M., Kireeva M.L., Kolesnikova T.V., and Lau L.F. CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc. Natl. Acad. Sci. USA 95 (1998) 6355-6360